NCT01668719: Phase 1/2 - S1211 Bort, Dex & Lenalidomide +/- Elotuzumab High Risk NDMM SWOG 1211
NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib
NCT01169337: Phase 3 -Lenalidomide or Observation in Asymptomatic High-Risk Smoldering Myeloma E3A06
NCT01109004: Phase 3 - Stem Cell Transplant With Lenalidomide Maint. NDMM BMT CTN 0702 (STaMINA)
NCT00644228 : Phase 3 - Lenalidomide and Dexamethasone + / - Bortezomib in NDMM - SWOG S0777
NCT00602641: Phase 3: Melphalan, Prednisone, and Thalidomide or Lenalidomide in NDMM Myeloma
NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With NDMM
NCT00478218: Phase 2 : Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating New Myeloma
NCT00114101: Phase 3 - CALGB 100104 - Lenalidomide in Patients With MM Undergoing Auto Transplant
NCT00098475: Phase 3: Lenalidomide and Dexamethasone With or Without Thalidomide in Multiple Myeloma
NCT00028886: Phase 3 - Combination Chemotherapy With or Without Thalidomide in Multiple Myeloma